ArticleClinical pharmacokinetics2026
Development and Validation of a Chinese Obesity-Specific Physiological Database for PBPK Modeling.
Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo develop and validate a physiologically based pharmacokinetic (PBPK) population model for the Chinese obese population.
methodsA Chinese adult population database was established in PK-Sim through recalibration of the East Asian population database, using newly collected anatomical and physiological data from Chinese adults. All three drugs (dexmedetomidine, omeprazole, and propofol) possessing Chinese obese population PK data were selected, with their PBPK models then developed and validated using matched clinical data. These models with the fixed drug-specific parameters were applied to the Chinese adult database to simulate drug concentrations, with results compared with the built-in East Asian database. Then, physiological parameters were adjusted using real-world and literature data from Chinese patients with obesity to establish a Chinese obese adult database. Similarly, drug concentrations in this population were simulated and compared with the simulation results based on the published White obese population database.
resultsThe predicted C
conclusionsThe validated drug models, combined with the Chinese adult and obese adult databases, reliably predicted drug concentrations in Chinese adults and adults with obesity, outperforming the East Asian population database and White obese population database.
Indexed as
Identifiers
41390893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.